Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | GCLC | P48506 | 2/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.36 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL150292 | 0.82 | TSHR (0.38) | CA2MAPK1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL61510 | 0.79 | FOLH1 (0.54) | CA2MAPK1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL26838933 | 0.79 | FOLH1 (0.54) | CA2MAPK1SLC1A3SLC1A2SLC1A1 | |
| Chloromethane SCHEMBL28143162 | 0.78 | CA2 (0.64) | CA2MAPK1SLC1A3SLC1A2SLC1A1 | |
| Methylene Chloride SCHEMBL7435842 | 0.78 | FOLH1 (0.48) | CA2MAPK1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL6114 | 0.78 | — | — | |
| Ammonia Solution, Strong SCHEMBL28859153 | 0.77 | FOLH1 (0.52) | CA2MAPK1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL10823502 | 0.77 | FOLH1 (0.52) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| Water SCHEMBL15665821 | 0.77 | FOLH1 (0.52) | CA2MAPK1SLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL4145272 | 0.77 | FOLH1 (0.52) | CA2MAPK1SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11117888-B2 | Irreversible inhibitors of pyruvate kinase M2 and the use thereof | CHINA MEDICAL UNIVERSITY (TW) | 2021-09-14 | — | — | US | disclosed |
| US-20210221801-A1 | Irreversible inhibitors of pyruvate kinase M2 and the use thereof | CHINA MEDICAL UNIVERSITY (TW) | 2021-07-22 | — | — | US | disclosed |
| EP-3237396-B1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | GENFIT (FR) | 2019-07-03 | — | — | EP | disclosed |
| EP-3237396-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | Genfit (FR) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016102633-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | GENFIT (FR) | 2016-06-30 | — | — | WO | disclosed |
| US-8729107-B2 | Pyridines for treating injured mammalian nerve tissue | PURDUE RESEARCH FOUNDATION (US) | 2014-05-20 | — | — | US | disclosed |
| US-8097638-B2 | Pyridines for treating injured mammalian nerve tissue | PURDUE RESEARCH FOUNDATION (US) | 2012-01-17 | — | — | US | disclosed |
| US-20110130429-A1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | PURDUE RESEARCH FOUNDATION (US) | 2011-06-02 | — | — | US | disclosed |
| EP-1567497-B1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | PURDUE RESEARCH FOUNDATION (US) | 2009-09-23 | — | — | EP | disclosed |
| US-20080039490-A1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | PURDUE RESEARCH FOUNDATION (US) | 2008-02-14 | — | — | US | disclosed |
| US-7244748-B2 | Pyridines for treating injured mammalian nerve tissue | PURDUE RESEARCH FOUNDATION (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1567497-A4 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | PURDUE RESEARCH FOUNDATION (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1567497-A2 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | Purdue Research Foundation (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040171587-A1 | Pyridines for treating injured mammalian nerve tissue | PURDUE RESEARCH FOUNDATION | 2004-09-02 | — | — | US | disclosed |
| WO-2004052291-A2 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | PURDUE RESEARCH FOUNDATION (US) | 2004-06-24 | — | — | WO | disclosed |
| US-6737275-B2 | OBTAINING SERUM; OBTAINING A REACTION MIXTURE OF AN ACRYLATING COMPOUND AND PERCHLORATE ION; REACTING TO PRODUCE COLORED PRODUCT; MEASURING SPECTRAL DATA FOR COLORED PRODUCT; APPLYING MULTIPLE WAVELENGTH DETECTIION WITH STATISTICAL ANALYSIS | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY | 2004-05-18 | — | — | US | disclosed |
| WO-2003025584-A2 | DIRECT SERUM LIPIDS ASSAYS FOR EVALUATION OF DISEASE STATES | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY (US) | 2003-03-27 | — | — | WO | disclosed |
| US-20020160519-A1 | Direct serum lipids assays for evaluation of disease states | BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY, THE | 2002-10-31 | — | — | US | disclosed |
| US-5030715-A | Antibacterial agents; immunomodulators; auto immune diseases | ROUSSEL UCLAF (FR) | 1991-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221801-A1 | Irreversible inhibitors of pyruvate kinase M2 and the use thereof | PDK2, PDK3, PDK4 | CA2 702/4885MAPK1 866/4885SLC1A3 2153/4885 |
| US-11117888-B2 | Irreversible inhibitors of pyruvate kinase M2 and the use thereof | PDK2, PDK3, PDK4 | CA2 702/4885MAPK1 866/4885SLC1A3 2153/4885 |
| US-20040171587-A1 | Pyridines for treating injured mammalian nerve tissue | P2RY4, INA, P2RY1 | CA2 993/4885MAPK1 2940/4885SLC1A3 986/4885 |
| US-20080039490-A1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | P2RY4, INA, PMP22 | CA2 971/4885MAPK1 2975/4885SLC1A3 965/4885 |
| US-20110130429-A1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | PMP22, SMN1; SMN2, MUSK | CA2 935/4885MAPK1 1814/4885SLC1A3 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.